Should travellers be offered vaccination against the dengue virus?

Dengue fever is expanding into new areas due to travel, climate change, urbanization, and the widening geographic range of the main vectors Ae.aegypti and Ae.albopictus [1].The newly licensed, tetravalent vaccine, Dengvaxia (CYD-TDV) by Sanofi Pasteur,has surprisingly been shown to increase the risk of severe dengue virus disease in persons not previously exposed to dengue virus. This has halted the roll out of the vaccine in endemic areas. In this editorial we argue that the new vaccine may have a place for travellers from non-endemic to endemic areas, who have previously experienced a dengue virus infection.
Source: Travel Medicine and Infectious Disease - Category: Infectious Diseases Authors: Source Type: research